Intent-to-treat median PFS was 10.2 months with nivolumab/ipilimumab versus 6.3 months with added SBRT, with 12-month PFS 47.8% versus 34.9% (HR 1.20; P=.56). Per-protocol analysis after four ...
At the 2026 Miami Breast Cancer Conference, Kevin Kalinsky, MD, MS, participated in a molecular tumor board session that brought together a multidisciplinary panel including medic ...
Aga Khan University Hospital, Nairobi (AKUH), has unveiled an AI-enabled radiotherapy system valued at KES 800 million, designed to deliver highly ...
New research from a University of Cincinnati Cancer Center study found external beam radiation therapy (EBRT) is safe to ...
New molecular insights into the link between hepatocellular carcinoma and intratumoral fibrosis could lead to better ...
The 2026 European Association of Urology (EAU) annual meeting featured an advancements in metastatic castration resistant prostate cancer (mCRPC) therapy session and a presentation by Dr. Giulio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results